A Phase 2 interventional study of L-carnitine and placebo in Complication of Hemodialysis, sponsored by Isfahan University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-01-19.
Sponsored by Isfahan University of Medical Sciences · Phase 2, Interventional, and Treatment
The purpose of this study is to determine Effect of oral L-carnitine supplement on lipid profile, anemia, and quality of life.
In patients under maintenance hemodialysis several factors reduce the body stored carnitine which in turn affected dyslipidemia, anemia, and general health in these patients. The investigators evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life in hemodialysis patients.
1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.
This study's enrollment of 54 is below the median of 99 across 842 interventional studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Isfahan University of Medical Sciences is the lead sponsor of 145 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
being in the age range of 18-75 having the history of at least 12 weeks of hemodialysis and at least three times a week and each session almost for four hours having serum triglyceride or total cholesterol concentration >200 mg/dl or serum HDL concentration >40 mg/dl in the beginning of the study.
Exclusion Criteria:
taking carnitine supplement or the drug that interact with carnation lowering the seizure threshold in the last month being affected by liver function abnormalities, hypothyroidism, chronic infectious diseases (such as hepatitis), inflammatory diseases, CNS mass having the history of seizure.
it is as like as L-carnitine in shape
Drug: placebo
it is kind of supplement
Drug: L-carnitine
500 mg,twice daily, 16 weeks
500 mg,twice daily, 16 weeks.
lipid profile
Time frame: at sixteen weeks after admission
anemia
Time frame: at sixteen weeks after admission
quality of life
Time frame: at sixteen weeks after admission
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Isfahan University of Medical Sciences